Clinical Trials Logo

Filter by:
  • Suspended  
  • Page [1]
NCT ID: NCT05935332 Suspended - Asthma Clinical Trials

Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

Start date: July 5, 2023
Phase: Phase 2
Study type: Interventional

Randomized, multi-center, double-blind, placebo-controlled, parallel group, proof of-concept study with RPT193 in subjects with T2-high, moderate-to-severe asthma who are partially controlled on medium or high doses of inhaled corticosteroids (ICS) in combination with long-acting beta 2 agonist (LABA).

NCT ID: NCT05178862 Suspended - Candidemia Clinical Trials

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

MARIO
Start date: August 3, 2022
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.

NCT ID: NCT04854512 Suspended - Clinical trials for Diabetes Mellitus, Type 2

Investigational Study of Delayed Release Metformin

DREAM-T2D
Start date: May 18, 2021
Phase: Phase 3
Study type: Interventional

In Phase 1 and 2 studies already conducted, Metformin DR, with its targeted delivery to the distal small intestine, has shown the potential to be a safe and effective way to improve glycemic control in patients with T2DM and CKD with less systemic metformin exposure. The primary purpose of this Phase 3 clinical study is to collect pivotal data confirming the safety and efficacy of Metformin DR in T2DM patients with varying renal function from normal up to CKD3B.